依諾替庫單抗

依諾替庫單抗
單克隆抗體
種類	完整抗體
目標	DLL4（英語：DLL4）
臨床資料
其他名稱	依諾蘇單抗、REGN421
ATC碼	未分配;
識別資訊
CAS號	1192578-27-0
ChemSpider	none;
UNII	B59DCD0F7D;
KEGG	D10460 ;

依諾替庫單抗（INN：Enoticumab；開發代號：REGN421），或譯依諾蘇單抗，是一種全人IgG₁（英語：IGHG1）單克隆抗體，可結合人DLL4（英語：DLL4）並破壞Notch介導的信號傳導。該藥物充當免疫調節劑。^[1]^[2]^[3]^[4]^[5]

參考資料

^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-20]. （原始內容存檔 (PDF)於2016-03-04）.
^ Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol. Cancer Ther. June 2016, 15 (6): 1344–52. PMC 4893925  . PMID 27009216. doi:10.1158/1535-7163.MCT-15-0144.
^ Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Res. October 2015, 75 (19): 4086–96. PMID 26377940. doi:10.1158/0008-5472.CAN-14-3773  .
^ Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin. Cancer Res. June 2015, 21 (12): 2695–703. PMID 25724527. doi:10.1158/1078-0432.CCR-14-2797  .
^ Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLOS ONE. 2014, 9 (11): e112371. Bibcode:2014PLoSO...9k2371M. PMC 4231048  . PMID 25393540. doi:10.1371/journal.pone.0112371  .

[1] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2) [2024-01-20]. （原始內容存檔 (PDF)於2016-03-04）.

[2] Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Mol. Cancer Ther. June 2016, 15 (6): 1344–52. PMC 4893925  . PMID 27009216. doi:10.1158/1535-7163.MCT-15-0144.

[3] Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Res. October 2015, 75 (19): 4086–96. PMID 26377940. doi:10.1158/0008-5472.CAN-14-3773  .

[4] Chiorean EG, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin. Cancer Res. June 2015, 21 (12): 2695–703. PMID 25724527. doi:10.1158/1078-0432.CCR-14-2797  .

[5] Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLOS ONE. 2014, 9 (11): e112371. Bibcode:2014PLoSO...9k2371M. PMC 4231048  . PMID 25393540. doi:10.1371/journal.pone.0112371  .

[1]

[2]

[3]

[4]

[5]